Peptides DB
Research-centric peptide and protocol reference hub
Study 18 of 22Liraglutide literatureRenal failure · Review2026

Adherence to the Mediterranean diet and its effects on the onset and progression of diabetic nephropathy: a systematic review.

Higher adherence to the Mediterranean diet may reduce the risk of diabetic nephropathy, but current evidence is insufficient to establish causality.

Read at Renal failureAdd to compare

Where it sits

this study against the rest of the liraglutide corpus
6
Preclinical
10
Observational
0
Open-label
2
Randomised
4
Reviews · this one

Summary and findings

This systematic review examined the association between adherence to the Mediterranean diet and the onset and progression of diabetic nephropathy in adults with diabetes or hyperglycemia. Six studies were included, with most showing a lower risk of diabetic nephropathy associated with higher adherence to the diet. However, two studies found no statistically significant associations.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
21% to 86% reduction in risk of DN with higher MD adherence.2026

Abstract

The authors’ words, as Renal failure supplied them

<h4>Background</h4>Diabetic nephropathy (DN) is the primary microvascular complication of diabetes mellitus (DM), contributing to chronic kidney disease, and end-stage renal failure. More than 247,000 individuals develop renal failure due to DM. Mediterranean diet (MD) associated with cardiometabolic benefits and potential renal protective effects, however, its relationship on the onset and progression of DN remains unclear.<h4>Objective</h4>To examine the association between adherence to the MD and the onset and progression of DN.<h4>Methods</h4>This systematic review was conducted in accordance with PRISMA 2020 guidelines. A comprehensive search was performed in PUBMED, EBSCO host and SCOPUS databases. Studies including adults with hyperglycemia, DM, or DN, regardless of comorbidities, examining adherence to the MD and renal outcomes. Methodological integrity was evaluated using the Newcastle-Ottawa Scale (NOS) and Jadad Scale. Due to heterogeneity across studies, results were synthesized narratively.<h4>Results</h4>Six studies met the inclusion criteria. Most studies demonstrated that higher adherence to the MD was associated with a lower risk or odds of DN, particularly among individuals with DM. Reported associations ranged from 21% to 86%, depending on adherence level and study design. Two studies found no statistically significant associations (<i>p</i> > 0.05).<h4>Limitations</h4>The small number of studies, their predominantly observational design, and geographic concentration limit the generalizability and preclude causal inference.<h4>Conclusion</h4>Higher adherence to the MD appears to be associated with a lower risk of DN; however, current evidence remains limited and insufficient to draw conclusions regarding causality or disease progression. Further high-quality studies are required.

Background

Diabetic nephropathy is a major complication of diabetes mellitus, leading to chronic kidney disease and end-stage renal failure. With over 247,000 individuals developing renal failure due to diabetes, understanding potential protective dietary factors is crucial. The Mediterranean diet is known for its cardiometabolic benefits, but its specific impact on diabetic nephropathy is not well established.

Methods

This systematic review followed PRISMA 2020 guidelines and included studies from PUBMED, EBSCO host, and SCOPUS databases. It focused on adults with hyperglycemia, diabetes, or diabetic nephropathy, assessing adherence to the Mediterranean diet and renal outcomes. Methodological quality was evaluated using the Newcastle-Ottawa Scale and Jadad Scale, with results synthesized narratively due to study heterogeneity.

Results

Six studies were included, showing a range of 21% to 86% reduction in the risk of diabetic nephropathy with higher adherence to the Mediterranean diet. However, two studies did not find statistically significant associations, with p-values greater than 0.05.

Interpretation

While the review suggests a potential protective effect of the Mediterranean diet against diabetic nephropathy, the evidence is limited by the observational nature of the studies and their geographic concentration. The effect sizes reported are statistically significant but may not be clinically significant without further high-quality research. The findings align with the known cardiometabolic benefits of the Mediterranean diet but require cautious interpretation.

Key findings

  • 21% to 86% reduction in risk of DN with higher MD adherence.
  • Two studies reported no significant associations (p > 0.05).
  • Six studies met inclusion criteria.
  • Predominantly observational design.
  • Geographic concentration limits generalizability.

Limitations

  • small number of studies
  • predominantly observational design
  • geographic concentration
  • limited generalizability
  • causal inference precluded

Elsewhere in the Liraglutide corpus

BEmerging Therapeutic Strategies for Infantile Obesity: A Narrative Reviewbiorxiv-preprint · 2026 · n=4331 · 1.71 kg/m² BMI reduction with medication plus behavioral treatment vs behavioral treatment alone, n=4331.reviewBPrevention of new-onset chronic kidney disease with renin-angiotensin system blockers in type 2 diabetes with preserved kidney function.Renal failure · 2026 · n=4725 · HR 0.72; 95% CI 0.60-0.86 for new-onset CKD with ACEI/ARB therapy.HumanBSGLT2 inhibitors versus GLP-1 receptor agonists and risk of kidney replacement therapy and healthcare utilization in bipolar disorder with chronic kidney disease: An active-comparator, new-user cohort study.Journal of affective disorders · 2026 · n=5114 · aHR 0.87, 95% CI 0.71-1.06 for KRT risk in full cohort.HumanCImportance of antibody validation in detecting cell cycle regulatory protein p16 &lt;sup&gt;&lt;b&gt;INK4A&lt;/b&gt;&lt;/sup&gt; by immunohistochemistry on pancreas tissue.Islets · 2026 · Not reported in abstract.In vitroDCompounded GLP-1 Drugs Remain Prevalent After Drug Shortage.JAMA · 2026BClinical practice patterns and unmet needs in the use of GLP-1 receptor agonists in sleep medicine: A pan-European survey performed in the European sleep apnoea database network.Pulmonology · 2026 · 42% of centres reported that GLP-1RA therapy could be initiated by sleep physicians within the sleep clinic.Human